Cellmid Ltd - New experienced Midkine CEO appointment
Cellmid Ltd (ASX:CDY)

New experienced Midkine CEO appointment

Published Oct 01, 2019

What happened?

New CEO Appointment - Bart Wuurman

On the 1st June 2019, Bart Wuurman became the CEO of Lyramid, which holds Cellmid's Midkine portfolio. Mr. Wuuran's mandate is to accelerate partnering discussions and to explore opportunities to fully exploit these assets.

A Trackrecord of Results:

Mr Wuurman has previously executed successful biotech deals including Antisoma in the UK via a successful IPO and Lanthio Pharma in the Netherland via a trade sale. At AM-Pharma, as CEO, he was instrumental in securing a €29 million funding round and a $600 million option deal with Pfizer.


Mr Wuurman is an accomplished biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing. In 2015 Mr Wuurman became Managing Director of DDF Ventures, a life-science fund with a portfolio of young life sciences companies.

CEO's summary

Maria Halasz CEO of Cellmid Ltd has provided a statement.
Maria Halasz
Maria Halasz
CEO, Cellmid Ltd

“We welcome Bart to the Cellmid leadership team and are very excited to work with him on the midkine portfolio. He has a track record of leading successful commercial deals in biotech and we see many opportunities for value creation in taking our midkine assets to the next level of clinical development.”

Video Overview

Watch and share a brief overview of this announcement.

Download Announcement

View this announcement as well as our full profile on the company.


Share your thoughts about this announcement...

Similar articles
Independent test results for the Wondfo SARS-COV-2 Test
What's happened? Cellmid Limited (ASX:CDY) has announced that a validation study has been completed for the Wondfo SARS-...
1 year ago
Cellmid share placement raises $6m to fund SARS-V-2 diagnostic test roll out
What's happened? Cellmid Limited (ASX:CDY) has raised $6 million (before costs) via a share placement from institutional...
1 year ago
Cellmid enter into supply agreement for COVID-19 rapid diagnostic test
What's happened? Cellmid Ltd (ASX: CDY, “Cellmid”) have announced that it has entered into a supply agreement for a COVI...
1 year ago
Around the web
Reporting Season Round Up: The good times roll on for COVID beneficiary stocks
In 2021 many COVID beneficiary stocks actually dropped following their financial results, as investo...
via stockhead.com.au
Why are ASX-listed stocks PBH, HNG, DCC on investors’ radar today?
Highlights PointsBet has been appointed as Austin FC’s Exclusive Sportsbook Partner through an e...
via kalkinemedia.com
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
The ASX 200 health stocks index (XHJ) has lifted by 0.46% at the time of writing, compared to the br...
via stockhead.com.au
Powered by  
  • Company
    Cellmid Ltd
  • Website
  • Sector
  • Industry
  • Code
  • Socials
View Cellmid Ltd's Profile

How do I invest?

Considering investing in Cellmid Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:CDY

    On your online investment platform search for the stock ticker code ASX:CDY to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.